Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

Forma’s $100 million in series D financing will fuel the company's push to join the wave of progress in sickle cell disease and complete its transformation from a chemistry research organization to a therapeutics company focused on blood disorders and cancer.

The financing is Forma Therapeutics Inc.’s first in seven years, as the bulk of the company’s funds in the interim have come from research partnerships. CEO Frank Lee told BioCentury Forma’s evolution was catalyzed by the January acquisition of major partner Celgene Corp. by Bristol-Myers Squibb Co. (NYSE:BMY). ...